Rubix LS
Rubix LS is the Health Outcomes Architect Company, dedicated to designing transformative health solutions for every community. They focus on holistic, precision-focused approaches that address biological, environmental, and socioeconomic factors affecting health. Their mission is to create a healthier future by improving health outcomes, especially for underserved populations, through innovative research, data-driven insights, and inclusive healthcare strategies.
Industries
Nr. of Employees
small (1-50)
Products
Large clinical data repository (multi‑million records)
A centrally managed, diverse clinical dataset containing over 12 million patient records to support cohort identification, epidemiology, and RWE analyses.
AI analytics and knowledge platform for drug development
A dual consulting and technology platform combining scientific AI analytics and curated data libraries to accelerate hit confirmation, lead optimization, and preclinical assessment.
Large clinical data repository (multi‑million records)
A centrally managed, diverse clinical dataset containing over 12 million patient records to support cohort identification, epidemiology, and RWE analyses.
AI analytics and knowledge platform for drug development
A dual consulting and technology platform combining scientific AI analytics and curated data libraries to accelerate hit confirmation, lead optimization, and preclinical assessment.
Services
Delivery of comprehensive clinical research services including protocol development, site operations, regulatory planning, and Phase I–II execution with emphasis on inclusivity and scale.
AI-driven analytics services for genomic, clinical, and real-world datasets to inform trial design, variant interpretation, and treatment stratification.
Operational, data, and methodological support for investigator-initiated studies, with emphasis on underserved populations and health equity.
Partnerships and contract research services tailored to federal agencies and public health initiatives, providing rapid, cross-disciplinary research support.
Early-stage regulatory planning, pre-IND guidance, and alignment with global regulatory requirements to reduce filing risk and accelerate approvals.
Consulting services covering trial design, dosing and endpoint selection, safety monitoring, and regulatory considerations specific to cellular therapies.
Delivery of comprehensive clinical research services including protocol development, site operations, regulatory planning, and Phase I–II execution with emphasis on inclusivity and scale.
AI-driven analytics services for genomic, clinical, and real-world datasets to inform trial design, variant interpretation, and treatment stratification.
Operational, data, and methodological support for investigator-initiated studies, with emphasis on underserved populations and health equity.
Partnerships and contract research services tailored to federal agencies and public health initiatives, providing rapid, cross-disciplinary research support.
Early-stage regulatory planning, pre-IND guidance, and alignment with global regulatory requirements to reduce filing risk and accelerate approvals.
Consulting services covering trial design, dosing and endpoint selection, safety monitoring, and regulatory considerations specific to cellular therapies.
Expertise Areas
- Clinical trial management
- Decentralized and adaptive trial design
- Clinical data analytics and real-world evidence
- Biomarker and genomic analysis
Key Technologies
- Generative AI for genomic analysis
- Machine learning for predictive recruitment
- Real-world evidence analytics
- Secure clinical data infrastructure (21 CFR Part 11 / CDISC-aligned)
News & Updates
Rubix LS is part of the worldwide initiative to fast-track gender equity in science, technology, and finance by 2030, collaborating with organizations like UNFPA, WHO, USAID, UNAIDS, and PATH to address global health equity challenges.
Partnership to develop innovative interstitial fluid and aptamer technologies for early cancer diagnostics.
Explores how generative AI is revolutionizing genomic data analysis, enabling personalized treatments, faster variant interpretation, and discovery of genetic associations.
Best practices for clinical researchers to ensure data validity and inclusivity across international sites with varying regulations and cultures.
Rubix LS has acquired and utilizes an extensive data repository featuring over 12 million diverse patient records, enhancing research and development of targeted therapies.
Rubix LS is part of the worldwide initiative to fast-track gender equity in science, technology, and finance by 2030, collaborating with organizations like UNFPA, WHO, USAID, UNAIDS, and PATH to address global health equity challenges.
Partnership to develop innovative interstitial fluid and aptamer technologies for early cancer diagnostics.
Explores how generative AI is revolutionizing genomic data analysis, enabling personalized treatments, faster variant interpretation, and discovery of genetic associations.
Best practices for clinical researchers to ensure data validity and inclusivity across international sites with varying regulations and cultures.
Rubix LS has acquired and utilizes an extensive data repository featuring over 12 million diverse patient records, enhancing research and development of targeted therapies.